MX2020011672A - Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal. - Google Patents

Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.

Info

Publication number
MX2020011672A
MX2020011672A MX2020011672A MX2020011672A MX2020011672A MX 2020011672 A MX2020011672 A MX 2020011672A MX 2020011672 A MX2020011672 A MX 2020011672A MX 2020011672 A MX2020011672 A MX 2020011672A MX 2020011672 A MX2020011672 A MX 2020011672A
Authority
MX
Mexico
Prior art keywords
present
tumor
relates
immune responses
avl9
Prior art date
Application number
MX2020011672A
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Steffen Walter
Peter Lewandrowski
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MX2020011672A publication Critical patent/MX2020011672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a péptidos, ácidos nucleicos y células para su utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia del cáncer. La presente invención se refiere además a epitopos peptídicos de linfocitos T citotóxicos asociados a tumores que sirven de ingredientes farmacéuticos activos de composiciones de vacunas que estimular las respuestas inmunitarias antitumorales. La presente invención refiere a 95 secuencias peptídicas novedosas y sus variantes derivadas de moléculas HLA de clase I de células de tumor humanas que pueden utilizarse en composiciones de vacunas para desencadenar respuestas inmunitarias antitumorales.
MX2020011672A 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal. MX2020011672A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31570410P 2010-03-19 2010-03-19
GBGB1004551.6A GB201004551D0 (en) 2010-03-19 2010-03-19 NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer

Publications (1)

Publication Number Publication Date
MX2020011672A true MX2020011672A (es) 2020-12-03

Family

ID=42227949

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2012010813A MX2012010813A (es) 2010-03-19 2011-03-15 Diagnostico y tratamiento de cancer basado en avl9.
MX2020011672A MX2020011672A (es) 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
MX2020011674A MX2020011674A (es) 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
MX2015001606A MX355074B (es) 2010-03-19 2012-09-19 Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal.
MX2020011673A MX2020011673A (es) 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
MX2020011675A MX2020011675A (es) 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012010813A MX2012010813A (es) 2010-03-19 2011-03-15 Diagnostico y tratamiento de cancer basado en avl9.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2020011674A MX2020011674A (es) 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
MX2015001606A MX355074B (es) 2010-03-19 2012-09-19 Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal.
MX2020011673A MX2020011673A (es) 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
MX2020011675A MX2020011675A (es) 2010-03-19 2012-09-19 Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.

Country Status (30)

Country Link
US (24) US10064913B2 (es)
EP (9) EP2547354B1 (es)
JP (9) JP5891181B2 (es)
KR (13) KR102388761B1 (es)
CN (8) CN112430255A (es)
AU (1) AU2011229199B2 (es)
BR (1) BR112012023692B1 (es)
CA (5) CA3076642C (es)
CY (5) CY1119366T1 (es)
DK (6) DK2547354T3 (es)
EA (8) EA202091241A3 (es)
ES (6) ES2544529T3 (es)
GB (1) GB201004551D0 (es)
HK (5) HK1180610A1 (es)
HR (6) HRP20150867T1 (es)
HU (6) HUE033682T2 (es)
LT (5) LT3363456T (es)
ME (3) ME02229B (es)
MX (6) MX2012010813A (es)
MY (2) MY178651A (es)
NZ (7) NZ708205A (es)
PH (2) PH12016500949A1 (es)
PL (6) PL3363456T3 (es)
PT (6) PT3329933T (es)
RS (6) RS54182B1 (es)
SG (4) SG10201606771SA (es)
SI (6) SI3195873T1 (es)
TW (9) TWI766362B (es)
UA (3) UA111711C2 (es)
WO (1) WO2011113819A2 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604662B2 (en) 2007-07-13 2009-10-20 Boston Scientific Scimed, Inc. Endoprostheses containing boride intermetallic phases
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP2400035A1 (en) * 2010-06-28 2011-12-28 Technische Universität München Methods and compositions for diagnosing gastrointestinal stromal tumors
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
JP6124149B2 (ja) * 2011-10-28 2017-05-10 オンコセラピー・サイエンス株式会社 Ｔｏｐｋペプチドおよびそれを含むワクチン
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP3855184B1 (en) * 2012-03-19 2023-12-27 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
ES2967342T3 (es) 2012-05-16 2024-04-29 Stemline Therapeutics Inc Vacunas contra el cáncer dirigidas a células madre cancerosas
US9687538B2 (en) * 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JP6212249B2 (ja) * 2012-08-08 2017-10-11 学校法人 京都産業大学 カルシウムポンプ制御物質のスクリーニング方法、並びに、メラニン色素合成阻害物質のスクリーニング方法
US9114157B2 (en) * 2012-08-30 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Anti-tumor T cell immunity induced by high dose radiation
RS62602B1 (sr) 2013-08-05 2021-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc
TWI777198B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015164826A2 (en) * 2014-04-24 2015-10-29 Rhode Island Hospital ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
KR101644599B1 (ko) 2014-10-14 2016-08-16 연세대학교 산학협력단 미토콘드리아 단백질 uqcrb 관련 질환 유전자발현 세포 구축 및 이를 활용한 uqcrb 기능조절 활성평가계 구축
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2017141243A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
TWI755158B (zh) 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
EP4140492A1 (en) 2015-04-21 2023-03-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
JP6838004B2 (ja) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
TWI751557B (zh) * 2015-06-19 2022-01-01 德商英麥提克生物技術股份有限公司 用於免疫治療的新穎胜肽及胜肽組合物與產生用於抗胰臟癌及其他癌症的支架的方法
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
TWI782433B (zh) 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10335471B2 (en) * 2015-08-28 2019-07-02 Immatics Biotechnologies Gmbh Method for treating cancer with activated T cells
KR102601499B1 (ko) * 2015-11-06 2023-11-13 연세대학교 산학협력단 miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
MA54832A (fr) 2016-03-01 2021-12-01 Immatics Biotechnologies Gmbh Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
SG10202006117QA (en) 2016-04-21 2020-08-28 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
PE20181897A1 (es) 2016-04-21 2018-12-11 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cancer
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR102381854B1 (ko) * 2016-08-17 2022-04-04 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN109923121B (zh) 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN110167956B (zh) * 2016-11-30 2023-04-07 深圳华大生命科学研究院 多肽及其应用
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
PE20191711A1 (es) * 2017-04-10 2019-11-28 Immatics Biotechnologies Gmbh Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
PE20200614A1 (es) 2017-07-14 2020-03-11 Immatics Biotechnologies Gmbh Molecula de polipeptido con especificidad dual mejorada
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
DE102017125888A1 (de) * 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
IL308007A (en) * 2017-11-06 2023-12-01 Immatics Biotechnologies Gmbh Transgenic T-cell receptors and immunotherapy using them
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
US20210380661A1 (en) * 2018-10-16 2021-12-09 Texas Tech University System Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
EA202193139A1 (ru) 2019-05-27 2022-03-01 Имматикс Юс, Инк. Вирусные векторы и их применение в адоптивной клеточной терапии
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
JP2022535421A (ja) 2019-06-06 2022-08-08 イマティクス バイオテクノロジーズ ゲーエムベーハー 配列類似ペプチドを使用した対抗選択による選別
KR102397922B1 (ko) * 2020-02-19 2022-05-13 서울대학교 산학협력단 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도
EP4206334A1 (en) 2020-08-28 2023-07-05 Industry Academic Cooperation Foundation Keimyung University Micro rna biomarker for predicting drug response to antidiabetics and use thereof
EP4247402A1 (en) * 2020-11-19 2023-09-27 Board of Regents, The University of Texas System Methods and compositions comprising mhc class i peptides
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
JP2024516699A (ja) 2021-05-05 2024-04-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｂｍａ０３１抗原結合ポリペプチド
CN114732898B (zh) * 2022-04-01 2023-05-09 中国人民解放军军事科学院军事医学研究院 一种CpG佐剂与抗原定点共价结合方法
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2024072954A1 (en) * 2022-09-29 2024-04-04 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine
WO2024077071A2 (en) * 2022-10-05 2024-04-11 The Johns Hopkins University Nanoparticles for delivery of immunoregulatory materials to t cells

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JP4767371B2 (ja) 1996-01-17 2011-09-07 インペリアル・イノベイションズ・リミテッド 細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US8299321B2 (en) 1998-06-16 2012-10-30 Monsanto Technology Llc Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1319133A (zh) * 1998-09-25 2001-10-24 儿童医疗中心有限公司 选择性地调节蛋白激酶活性的短肽
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2393738A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
JP4310104B2 (ja) 2002-09-28 2009-08-05 英俊 猪子 マイクロサテライト遺伝多型マーカを用いる遺伝子のマッピング方法
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20070067865A1 (en) 2000-09-05 2007-03-22 Kovalic David K Annotated plant genes
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US20040110668A1 (en) 2000-10-02 2004-06-10 Burgess Christopher C. Nucleic acid sequences differentially expressed in cancer tissue
US6673549B1 (en) * 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
WO2002036614A2 (en) * 2000-11-01 2002-05-10 Insight Biotechnology Limited Peptides for use in the treatment of alzheimer's disease
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002078524A2 (en) * 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002078516A2 (en) * 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
AU2003304464A1 (en) 2002-03-15 2005-03-29 Monsanto Technology Llc Nucleic acid molecules associated with oil in plants
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
AU2002368151A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2005049806A2 (en) * 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20070037204A1 (en) * 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
WO2005072050A2 (en) * 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US20070039069A1 (en) 2004-03-22 2007-02-15 Rogers James A Nucleic acid molecules associated with oil in plants
EP1737979B9 (en) 2004-03-23 2011-09-21 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
AT501014A1 (de) * 2004-08-19 2006-05-15 Kury & Zeillinger Oeg Verfahren und kit zur diagnose einer krebserkrankung, verfahren zum feststellen des ansprechens eines patienten auf die behandlung einer krebserkrankung, therapeutikum zur prophylaxe oder behandlung einer krebserkrankung
US8435507B2 (en) * 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2007005635A2 (en) * 2005-07-01 2007-01-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor
ATE440107T1 (de) * 2005-09-05 2009-09-15 Immatics Biotechnologies Gmbh Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
ES2341802T3 (es) * 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
GB0521958D0 (en) * 2005-10-27 2005-12-07 Ares Trading Sa vWFA, collagen and kunitz domain containing protein
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
PT2567707T (pt) * 2007-07-27 2016-12-27 Immatics Biotechnologies Gmbh Composição de péptidos associados a tumores e vacina anticancro relacionada
CN105566450A (zh) * 2007-07-27 2016-05-11 伊玛提克斯生物技术有限公司 免疫疗法的新型免疫抗原表位
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ATE462442T1 (de) 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
US8133686B2 (en) * 2008-05-15 2012-03-13 Van Andel Research Institute IL-8 as a biomarker for sunitinib resistance
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201015765D0 (en) * 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer

Also Published As

Publication number Publication date
CN108456242A (zh) 2018-08-28
HUE051478T2 (hu) 2021-03-01
SI3363456T1 (sl) 2021-02-26
RS59554B1 (sr) 2019-12-31
SI2923708T1 (sl) 2017-10-30
US10357540B2 (en) 2019-07-23
CN112430255A (zh) 2021-03-02
KR102324500B1 (ko) 2021-11-09
US11273200B2 (en) 2022-03-15
JP2020191875A (ja) 2020-12-03
HRP20201467T1 (hr) 2020-12-11
JP2018057393A (ja) 2018-04-12
HRP20201770T1 (hr) 2021-03-19
CA3076642A1 (en) 2011-09-22
EP2845604A2 (en) 2015-03-11
HRP20170718T1 (hr) 2017-07-14
HK1255544A1 (zh) 2019-08-23
ES2829375T3 (es) 2021-05-31
TW202102536A (zh) 2021-01-16
KR20220025133A (ko) 2022-03-03
CN105001339B (zh) 2020-10-16
EP2547354B1 (en) 2015-06-03
US10420816B1 (en) 2019-09-24
KR20200108935A (ko) 2020-09-21
HUE027036T2 (en) 2016-08-29
NZ627877A (en) 2015-08-28
MY197710A (en) 2023-07-09
PL2547354T3 (pl) 2015-12-31
KR20180014848A (ko) 2018-02-09
KR20200108934A (ko) 2020-09-21
US11975042B2 (en) 2024-05-07
RS54182B1 (en) 2015-12-31
JP6238258B2 (ja) 2017-11-29
DK2845604T3 (da) 2017-05-01
US9717774B2 (en) 2017-08-01
TW201529849A (zh) 2015-08-01
LT3363456T (lt) 2021-01-11
EA202091233A3 (ru) 2020-12-30
US11957730B2 (en) 2024-04-16
CA2986969A1 (en) 2011-09-22
CA2789857A1 (en) 2011-09-22
US20220016209A1 (en) 2022-01-20
MY178651A (en) 2020-10-20
US10478471B2 (en) 2019-11-19
EP3195873B1 (en) 2019-07-24
TW201825514A (zh) 2018-07-16
BR112012023692A2 (pt) 2017-07-18
US20210162004A1 (en) 2021-06-03
US20220265764A1 (en) 2022-08-25
JP5891181B2 (ja) 2016-03-22
UA111711C2 (uk) 2016-06-10
SI2845604T1 (sl) 2017-06-30
PL3195873T3 (pl) 2020-03-31
LT3195873T (lt) 2019-11-11
HRP20191859T1 (hr) 2019-12-27
EA024497B1 (ru) 2016-09-30
EA039357B1 (ru) 2022-01-18
TWI766362B (zh) 2022-06-01
DK3195873T3 (da) 2019-10-21
ME02692B (me) 2017-10-20
KR20200109390A (ko) 2020-09-22
WO2011113819A3 (en) 2011-11-10
US11850274B2 (en) 2023-12-26
DK3363456T3 (da) 2020-11-09
CY1123447T1 (el) 2021-12-31
NZ708205A (en) 2015-09-25
PT3329933T (pt) 2020-09-22
DK2547354T3 (da) 2015-07-20
AU2011229199B2 (en) 2015-01-22
TW202102535A (zh) 2021-01-16
TWI766361B (zh) 2022-06-01
EA201792409A3 (ru) 2018-07-31
US20190290727A1 (en) 2019-09-26
US20220016207A1 (en) 2022-01-20
EA202091251A3 (ru) 2020-12-30
EP3363456A1 (en) 2018-08-22
JP2020191874A (ja) 2020-12-03
ES2626798T3 (es) 2017-07-26
HUE033682T2 (en) 2017-12-28
WO2011113819A2 (en) 2011-09-22
SG10201502093QA (en) 2015-05-28
HRP20171504T1 (hr) 2017-11-17
HRP20150867T1 (hr) 2015-09-25
JP6103608B2 (ja) 2017-03-29
US20110229504A1 (en) 2011-09-22
PL2923708T3 (pl) 2018-03-30
MX2020011674A (es) 2020-12-03
KR102388761B1 (ko) 2022-04-20
JP2013521789A (ja) 2013-06-13
EA202091242A2 (ru) 2021-01-29
EP3753570A1 (en) 2020-12-23
KR102324498B1 (ko) 2021-11-09
LT3329933T (lt) 2020-09-25
LT2923708T (lt) 2017-10-10
TW201200594A (en) 2012-01-01
US10898546B2 (en) 2021-01-26
EP3363456B1 (en) 2020-08-05
KR102361467B1 (ko) 2022-02-14
EP3738606A1 (en) 2020-11-18
RS60993B1 (sr) 2020-11-30
NZ737956A (en) 2020-11-27
EP2845604B1 (en) 2017-03-08
CY1119366T1 (el) 2018-02-14
MX2020011675A (es) 2020-12-03
ME03569B (me) 2020-07-20
CN105001339A (zh) 2015-10-28
US20150147347A1 (en) 2015-05-28
KR20160106192A (ko) 2016-09-09
UA126787C2 (uk) 2023-02-08
SI3329933T1 (sl) 2021-01-29
CA2789857C (en) 2017-03-21
CY1122235T1 (el) 2020-11-25
BR112012023692B1 (pt) 2020-06-09
LT2845604T (lt) 2017-04-25
EA202091250A3 (ru) 2020-12-30
JP2017006136A (ja) 2017-01-12
TWI681967B (zh) 2020-01-11
EP3195873A1 (en) 2017-07-26
US10064913B2 (en) 2018-09-04
HK1226297A1 (zh) 2017-09-29
EP2547354A2 (en) 2013-01-23
JP7034505B2 (ja) 2022-03-14
KR101826460B1 (ko) 2018-02-06
US20180000896A1 (en) 2018-01-04
US20210275634A1 (en) 2021-09-09
EA202091241A3 (ru) 2021-04-30
NZ769435A (en) 2023-02-24
EA201201306A1 (ru) 2013-02-28
EA201792409A2 (ru) 2018-03-30
CN112457390A (zh) 2021-03-09
EP2845604A3 (en) 2015-05-20
DK2923708T3 (en) 2017-10-16
PL2845604T3 (pl) 2017-09-29
NZ601438A (en) 2014-12-24
JP6722644B2 (ja) 2020-07-15
EP3058947A2 (en) 2016-08-24
AU2011229199A1 (en) 2012-08-16
HUE050376T2 (hu) 2020-11-30
SG10201710446PA (en) 2018-01-30
SG10201606771SA (en) 2016-10-28
EA202091233A2 (ru) 2020-09-30
KR20230141886A (ko) 2023-10-10
TW202026308A (zh) 2020-07-16
PT2923708T (pt) 2017-10-06
PH12019502194A1 (en) 2020-06-15
JP2021080263A (ja) 2021-05-27
PT2845604T (pt) 2017-06-01
EA202091250A2 (ru) 2020-09-30
CA2986969C (en) 2020-04-28
JP7007504B2 (ja) 2022-02-10
US11969455B2 (en) 2024-04-30
KR20210019139A (ko) 2021-02-19
RS56612B1 (sr) 2018-02-28
US20180125929A1 (en) 2018-05-10
PL3329933T3 (pl) 2020-11-30
CN112409452A (zh) 2021-02-26
CA2936642C (en) 2019-03-05
KR20200109389A (ko) 2020-09-22
JP7107586B2 (ja) 2022-07-27
PH12016500949B1 (en) 2017-02-13
PT3195873T (pt) 2019-10-31
EP3058947A3 (en) 2016-11-30
EP3329933B1 (en) 2020-06-24
EA202091241A2 (ru) 2021-01-29
EA201690511A1 (ru) 2016-11-30
ES2642562T3 (es) 2017-11-16
KR20200109392A (ko) 2020-09-22
US20170312336A1 (en) 2017-11-02
PH12016500949A1 (en) 2017-02-13
ES2753206T3 (es) 2020-04-07
CA3076642C (en) 2023-08-29
CY1119739T1 (el) 2018-06-27
US20190321442A1 (en) 2019-10-24
US20200155645A1 (en) 2020-05-21
TWI621709B (zh) 2018-04-21
TWI486445B (zh) 2015-06-01
GB201004551D0 (en) 2010-05-05
PT3363456T (pt) 2020-11-10
SG183880A1 (en) 2012-10-30
NZ727841A (en) 2019-11-29
TWI768461B (zh) 2022-06-21
CY1123762T1 (el) 2022-03-24
US10933118B2 (en) 2021-03-02
ES2544529T3 (es) 2015-09-01
MX2020011673A (es) 2020-12-03
KR20130016304A (ko) 2013-02-14
EA202091251A2 (ru) 2020-09-30
KR102324499B1 (ko) 2021-11-09
TW202102534A (zh) 2021-01-16
DK3329933T3 (da) 2020-09-21
SI3195873T1 (sl) 2019-11-29
JP6535040B2 (ja) 2019-06-26
US10905741B2 (en) 2021-02-02
PT2547354E (pt) 2015-09-16
CA2936642A1 (en) 2011-09-22
JP2017140027A (ja) 2017-08-17
HK1180610A1 (en) 2013-10-25
HUE032402T2 (en) 2017-09-28
NZ769427A (en) 2023-02-24
KR102388577B1 (ko) 2022-04-19
US11883462B2 (en) 2024-01-30
RS60765B1 (sr) 2020-10-30
TW201805301A (zh) 2018-02-16
US11648292B2 (en) 2023-05-16
KR20210019603A (ko) 2021-02-22
TW202300509A (zh) 2023-01-01
CA3206214A1 (en) 2011-09-22
JP2022141743A (ja) 2022-09-29
US11298404B2 (en) 2022-04-12
NZ711296A (en) 2017-03-31
US20200297801A1 (en) 2020-09-24
SI2547354T1 (sl) 2015-09-30
JP2016034950A (ja) 2016-03-17
CN102905721B (zh) 2015-09-23
PL3363456T3 (pl) 2021-05-04
US20130045191A1 (en) 2013-02-21
KR101656913B1 (ko) 2016-09-13
US9101585B2 (en) 2015-08-11
TWI715332B (zh) 2021-01-01
RS56070B1 (sr) 2017-10-31
EP2923708B1 (en) 2017-07-12
ES2819861T3 (es) 2021-04-19
US20200330552A1 (en) 2020-10-22
US20220008506A1 (en) 2022-01-13
US20220040259A1 (en) 2022-02-10
EA202091242A3 (ru) 2021-04-30
US9993523B2 (en) 2018-06-12
EP2923708A1 (en) 2015-09-30
EA037019B1 (ru) 2021-01-27
US20210260160A1 (en) 2021-08-26
US20210346465A1 (en) 2021-11-11
HUE045757T2 (hu) 2020-01-28
MX355074B (es) 2018-04-04
TWI659967B (zh) 2019-05-21
UA122047C2 (uk) 2020-09-10
MX2012010813A (es) 2012-11-12
CN102905721A (zh) 2013-01-30
US11839643B2 (en) 2023-12-12
US20210268063A1 (en) 2021-09-02
CN112409451A (zh) 2021-02-26
ME02229B (me) 2016-02-20
US11077171B2 (en) 2021-08-03
CN112409453A (zh) 2021-02-26
US20210346466A1 (en) 2021-11-11
US20210330743A1 (en) 2021-10-28
HK1210586A1 (en) 2016-04-29
HK1208174A1 (en) 2016-02-26
US9895415B2 (en) 2018-02-20
KR102329791B1 (ko) 2021-11-22
NZ731580A (en) 2020-11-27
EP3329933A1 (en) 2018-06-06
KR20190033577A (ko) 2019-03-29
US20170304399A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
PH12019502194A1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2010001086A (es) Nueva inmunoterapia contra tumores neuronales y cerebrales.
EP4253401A3 (en) Personalized immunotherapy against several neuronal and brain tumors
PH12016502008A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml)
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc